BHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 127.1% based on the discounted cash flow analysis.
| Market cap | $2.12 Billion |
|---|---|
| Enterprise Value | $2.09 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.43 |
| Beta | 0.37 |
| Outstanding Shares | 375,000,000 |
| P/E Ratio | -1.92 |
|---|---|
| PEG | -2.59 |
| Price to Sales | 0.27 |
| Price to Book Ratio | -1.9 |
| Enterprise Value to Revenue | 0.26 |
| Enterprise Value to EBIT | 0.98 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | -0.49 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.3627▲ 44.27% |
|---|---|
| Total Calls | 3,863,700▲ 105.14% |
| Total Puts | 9,128,700▲ 152.45% |
Holdings and activity of institutional investors.
| Ownership % | 63.82%▲ 1.39% |
|---|---|
| Total Invested | $1.19B▼ 5.95% |
| Investors Holding | 243▼ 3.00% |
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...